MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

Acta Neuropathol. 2008 Feb;115(2):261-2. doi: 10.1007/s00401-007-0279-5. Epub 2007 Oct 10.

Authors

Kalman Kovacs, Bernd W Scheithauer, Matilde Lombardero, Roger E McLendon, Luis V Syro, Humberto Uribe, Leon D Ortiz, Luis C Penagos

PMID: 17926052
DOI: 10.1007/s00401-007-0279-5

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use*
DNA Modification Methylases / biosynthesis*
DNA Repair Enzymes / biosynthesis*
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Drug Resistance, Neoplasm / physiology*
Humans
Immunohistochemistry
Male
Middle Aged
Pituitary Neoplasms / drug therapy*
Pituitary Neoplasms / metabolism
Temozolomide
Tumor Suppressor Proteins / biosynthesis*

Substances

Antineoplastic Agents, Alkylating
Tumor Suppressor Proteins
Dacarbazine
DNA Modification Methylases
MGMT protein, human
DNA Repair Enzymes
Temozolomide